Ameritas Investment Partners’s ANI Pharmaceuticals ANIP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $154K | Buy |
1,865
+346
| +23% | +$27.8K | ﹤0.01% | 1565 |
|
|
2026
Q1 | $117K | Hold |
1,519
| – | – | ﹤0.01% | 1595 |
|
|
2025
Q4 | $120K | Hold |
1,519
| – | – | ﹤0.01% | 1592 |
|
|
2025
Q3 | $139K | Sell |
1,519
-293
| -16% | -$23.9K | ﹤0.01% | 1478 |
|
|
2025
Q2 | $118K | Hold |
1,812
| – | – | ﹤0.01% | 1638 |
|
|
2025
Q1 | $121K | Hold |
1,812
| – | – | ﹤0.01% | 1571 |
|
|
2024
Q4 | $100K | Hold |
1,812
| – | – | ﹤0.01% | 1779 |
|
|
2024
Q3 | $108K | Hold |
1,812
| – | – | ﹤0.01% | 1724 |
|
|
2024
Q2 | $115K | Buy |
1,812
+356
| +24% | +$23.1K | ﹤0.01% | 1634 |
|
|
2024
Q1 | $101K | Hold |
1,456
| – | – | ﹤0.01% | 1733 |
|
|
2023
Q4 | $80.3K | Hold |
1,456
| – | – | ﹤0.01% | 1883 |
|
|
2023
Q3 | $84.5K | Buy |
1,456
+436
| +43% | +$25.2K | ﹤0.01% | 1773 |
|
|
2023
Q2 | $54.9K | Hold |
1,020
| – | – | ﹤0.01% | 1991 |
|
|
2023
Q1 | $40.5K | Hold |
1,020
| – | – | ﹤0.01% | 2106 |
|
|
2022
Q4 | $43.8K | Buy |
1,020
+239
| +31% | +$8.98K | ﹤0.01% | 2144 |
|
|
2022
Q3 | $25K | Hold |
781
| – | – | ﹤0.01% | 2400 |
|
|
2022
Q2 | $23K | Hold |
781
| – | – | ﹤0.01% | 2483 |
|
|
2022
Q1 | $22K | Hold |
781
| – | – | ﹤0.01% | 2511 |
|
|
2021
Q4 | $36K | Hold |
781
| – | – | ﹤0.01% | 2330 |
|
|
2021
Q3 | $26K | Hold |
781
| – | – | ﹤0.01% | 2551 |
|
|
2021
Q2 | $27K | Hold |
781
| – | – | ﹤0.01% | 2563 |
|
|
2021
Q1 | $28K | Hold |
781
| – | – | ﹤0.01% | 2401 |
|
|
2020
Q4 | $23K | Hold |
781
| – | – | ﹤0.01% | 2397 |
|
|
2020
Q3 | $22K | Hold |
781
| – | – | ﹤0.01% | 2315 |
|
|
2020
Q2 | $25K | Hold |
781
| – | – | ﹤0.01% | 2227 |
|
|
2020
Q1 | $32K | Hold |
781
| – | – | ﹤0.01% | 1904 |
|
|
2019
Q4 | $48K | Hold |
781
| – | – | ﹤0.01% | 1948 |
|
|
2019
Q3 | $57K | Hold |
781
| – | – | ﹤0.01% | 1806 |
|
|
2019
Q2 | $64K | Buy |
781
+165
| +27% | +$11.7K | ﹤0.01% | 1770 |
|
|
2019
Q1 | $43K | Hold |
616
| – | – | ﹤0.01% | 1966 |
|
|
2018
Q4 | $28K | Hold |
616
| – | – | ﹤0.01% | 2135 |
|
|
2018
Q3 | $35K | Hold |
616
| – | – | ﹤0.01% | 2186 |
|
|
2018
Q2 | $41K | Hold |
616
| – | – | ﹤0.01% | 2107 |
|
|
2018
Q1 | $36K | Hold |
616
| – | – | ﹤0.01% | 2092 |
|
|
2017
Q4 | $40K | Hold |
616
| – | – | ﹤0.01% | 2040 |
|
|
2017
Q3 | $29K | Hold |
616
| – | – | ﹤0.01% | 2204 |
|
|
2017
Q2 | $29K | Hold |
616
| – | – | ﹤0.01% | 2242 |
|
|
2017
Q1 | $30K | Buy |
+616
| New | +$34.6K | ﹤0.01% | 2154 |
|
Other funds holding ANIP
TCM
GACM
Ameritas Investment Partners's ANIP Position: Q2 2026 in Review
Ameritas Investment Partners increased its ANI Pharmaceuticals (ANIP) stake by 23% in Q2 2026, buying an estimated $27.8K and bringing the position to 1,865 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #1565.
Ameritas Investment Partners first reported a position in ANIP in Q1 2017 and has held it in 38 quarters since. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.
- Ameritas Investment Partners held 1,865 shares of ANI Pharmaceuticals worth $154K as of Q2 2026.
- Ameritas Investment Partners bought 346 ANI Pharmaceuticals shares in Q2 2026, an estimated $27.8K.
- ANI Pharmaceuticals made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1565 holding.
- Ameritas Investment Partners first reported a position in ANI Pharmaceuticals in Q1 2017 and has held it in 38 quarters since.
- 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.
Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.